AZN : Analysis & Opinions

  1. Mega Deals: Why the Outlook Is Uncertain

    January 2, 2017
    The global M&A landscape could change in 2017 as new policies could hinder deal making.
  2. AstraZeneca Cuts 700 Jobs, Citing Falling Revenues

    December 9, 2016
    Falling revenues from its best-selling drugs have led to severe cost-cutting measures.
  3. AstraZeneca: Nexium Pay-For-Delay Win Upheld (AZN)

    November 23, 2016
    The verdict offers relief to the entire pharma industry, as it could have changed how branded and generic drugmakers handle ...
  4. FDA Lifts Hold on AstraZeneca's Cancer Trial (AZN)

    November 15, 2016
    AstraZeneca has resumed patient enrollment in a cancer drug study after the FDA lift its partial hold.
  5. These Drugs Led Medicare Spending (GILD, SNY)

    November 15, 2016
    Gilead's hepatitis C drug Harvoni accounted for $7 billion in total spending by Medicare in 2015.
  6. FDA Pauses Two AstraZeneca Cancer Studies (AZN)

    October 28, 2016
    The FDA placed a partial hold on two AstraZeneca Phase 3 studies for head and neck cancer.
  7. Drug Wars: California Vote Could Limit Price Hikes

    October 19, 2016
    Major drug companies have spent $60 million to defeat a referendum calling for price limits
  8. Thomas Mistele’s Q2 Healthcare Picks (AZN, CI)

    September 13, 2016
    Thomas Mistele’s hedge fund, Dodge & Cox, maintains a diverse portfolio valued at more than $100 billion, with healthcare ...
  9. Pfizer Inks a $1.6 Billion Deal with AstraZeneca

    August 25, 2016
    In light of its recent acquisition activity, Pfizer's (NYSE: PFE) latest asset purchase might seem small, but it's nevertheless ...
  10. A Look Inside the iShares International Select Dividend ETF (IDV, ...

    July 8, 2016
    The IDV, which has $2.75 trillion in net assets, is designed to track the results of high dividend paying equities in non-U.S. ...
  11. How to Short the FTSE Ahead of The Brexit Vote

    June 20, 2016
    Those who believe that a Brexit is likely can position themselves to take advantage of a fall in British stocks by taking ...
  12. AstraZeneca Monetizes Anesthetics Marketing for $770 million ...

    June 10, 2016
    Will the monetization of anesthetics marketing rights payoff for AstraZeneca?
  13. Global Health Care Technology: 5 Key Industry Players (JNJ, GSK)

    April 27, 2016
    Discover how to analyze which of these top five key global health care technology industry players best suit your portfolio ...
  14. 5 Best Dividend-Paying International Equity ETFs (SDIV, LVL)

    April 7, 2016
    Discover five of the highest dividend-yielding ETFs that are available for investors seeking portfolio exposure to international ...
  15. AstraZeneca Makes a $575 Million Acquisition (AZN, PFE)

    December 16, 2015
    Pharmaceutical giant AstraZeneca (NYSE: AZN) is shoring up its presence in a key segment. On Wednesday, the company announced ...
  16. New York AG Opens Exxon-Mobile Investigation, AstraZeneca to ...

    November 6, 2015
    New York state attorney general Eric Schneiderman announced yesterday that he would be launching an investigation into energy ...
  17. Pfizer CEO: The Story Behind Ian Read (PFE, AZN)

    June 3, 2015
    Learn about the rise of Ian Read, the CEO of Pfizer. Pfizer is one of the most profitable and largest pharmaceutical companies ...
  18. Amgen Takes a Hit, Shelves Potential Blockbuster (AMGN, AZN)

    May 29, 2015
    Amgen's (NASDAQ: AMGN) investors learned this past week that the company is walking away from its deal with AstraZeneca (NYSE: ...
  19. Houston, Johnson & Johnson May Have a Problem (JNJ, AZN)

    May 19, 2015
    When it comes to potential "safe haven" investments, healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is often ...
  20. 3 Top Pharma Stocks that Pay Regular Dividends (GSK, AZN)

    May 1, 2015
    The low down on three big name, dividend-paying pharma stocks.
  21. How the UK Makes Money

    April 29, 2015
    The United Kingdom has one of the strongest economies in the world thanks to the strength of its services, manufacturing ...
  22. Johnson & Johnson's New Billion-Dollar Blockbuster (AZN, JNJ)

    April 17, 2015
    Invokana, one of Johnson & Johnson's (NYSE: JNJ) newest drugs, was a bright spot in the company's otherwise lackluster ...
  23. Johnson & Johnson Earnings: 5 Key Things to Watch (JNJ, AZN)

    April 10, 2015
    Earnings season is readying to kick off in a big way, and within the health care sector most eyes are beginning to shift ...
  24. Interested In Pharmaceutical Stocks? Try Novartis (ADR)

    February 26, 2015
    Novartis AG, is the world's leading pharmaceutical company by sales. Here is a closer look at Novartis, and how its financials ...
  25. What Are The Best Bets In Biotech?

    May 2, 2014
    The NASDAQ Biotechnology Index is off nearly 20% as its components busy themselves with hostile bids and frenzied buying ...
  26. The United Kingdom Is Ripe For Stock Pickers

    December 6, 2013
    With the situation in Europe finally moving ahead, investors may want to focus on the United Kingdom. Stocks within the nation ...
  27. Will Immunotherapy Disrupt The Oncology Market?

    August 20, 2013
    Immunotherapy could radically change the treatment of cancer, and the revenue opportunities for pharmaceutical companies.
  28. Blue Chip Stocks Paying The Highest Dividends

    October 25, 2012
    While picking individual stocks is risky, these blue chip companies have histories that show they can be good choices.
  29. The Overlooked Dental Health Sector

    August 25, 2011
    While health care remains a great long-term portfolio position, many investors ignore the dental sub-sector. However, benefiting ...
  30. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others. ...